Free Trial
NYSE:CANF

Can-Fite BioPharma (CANF) Stock Price, News & Analysis

Can-Fite BioPharma logo
$0.71 +0.01 (+1.73%)
Closing price 04:00 PM Eastern
Extended Trading
$0.70 -0.01 (-1.47%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Can-Fite BioPharma Stock (NYSE:CANF)

Key Stats

Today's Range
$0.67
$0.73
50-Day Range
$0.70
$1.14
52-Week Range
$0.67
$3.33
Volume
496,174 shs
Average Volume
216,140 shs
Market Capitalization
$2.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00
Consensus Rating
Buy

Company Overview

Can-Fite BioPharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

CANF MarketRank™: 

Can-Fite BioPharma scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Can-Fite BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Can-Fite BioPharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Can-Fite BioPharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Can-Fite BioPharma are expected to grow in the coming year, from ($1.25) to ($0.05) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Can-Fite BioPharma is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Can-Fite BioPharma is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Can-Fite BioPharma has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.74% of the float of Can-Fite BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Can-Fite BioPharma has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Can-Fite BioPharma has recently increased by 353.42%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Can-Fite BioPharma does not currently pay a dividend.

  • Dividend Growth

    Can-Fite BioPharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.74% of the float of Can-Fite BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Can-Fite BioPharma has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Can-Fite BioPharma has recently increased by 353.42%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Can-Fite BioPharma has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Can-Fite BioPharma this week, compared to 1 article on an average week.
  • Search Interest

    3 people have searched for CANF on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.80% of the stock of Can-Fite BioPharma is held by insiders.

  • Percentage Held by Institutions

    Only 21.00% of the stock of Can-Fite BioPharma is held by institutions.

  • Read more about Can-Fite BioPharma's insider trading history.
Receive CANF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CANF Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Can-Fite Announces Up To $15.0 Million Public Offering
CANF Can-Fite BioPharma Ltd. - Seeking Alpha
See More Headlines

CANF Stock Analysis - Frequently Asked Questions

Can-Fite BioPharma's stock was trading at $1.6250 at the start of the year. Since then, CANF stock has decreased by 56.1% and is now trading at $0.7135.

Can-Fite BioPharma Ltd. (NYSE:CANF) released its earnings results on Tuesday, November, 30th. The company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($0.90) by $1.00. The firm had revenue of $0.25 million for the quarter.

Shares of Can-Fite BioPharma reverse split on Monday, January 9th 2023.The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Can-Fite BioPharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Meta Platforms (META), Broadcom (AVGO), Novo Nordisk A/S (NVO) and Adobe (ADBE).

Company Calendar

Last Earnings
11/30/2021
Today
7/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:CANF
CIK
1536196
Employees
8
Year Founded
N/A

Price Target and Rating

High Price Target
$18.00
Low Price Target
$10.00
Potential Upside/Downside
+1,863.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.93
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$674 thousand
Price / Sales
3.74
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.76 per share
Price / Book
0.41

Miscellaneous

Outstanding Shares
3,540,000
Free Float
N/A
Market Cap
$2.52 million
Optionable
Not Optionable
Beta
1.11
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NYSE:CANF) was last updated on 7/29/2025 by MarketBeat.com Staff
From Our Partners